These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 24349027)

  • 21. Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model.
    Qiao J; Li H; Li M
    Neuropsychopharmacology; 2013 Feb; 38(3):513-24. PubMed ID: 23132270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
    Bédard AM; Maheux J; Lévesque D; Samaha AN
    Schizophr Bull; 2013 May; 39(3):692-702. PubMed ID: 22927669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.
    Cooper GD; Pickavance LC; Wilding JP; Harrold JA; Halford JC; Goudie AJ
    J Psychopharmacol; 2007 Jun; 21(4):405-13. PubMed ID: 17050655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.
    Bilgic S; Tastemir Korkmaz D; Azirak S; Guvenc AN; Kocaman N; Ozer MK
    Bratisl Lek Listy; 2017; 118(10):618-625. PubMed ID: 29198130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.
    Turczyński J; Bidzan L; Staszewska-Małys E
    Med Sci Monit; 2004 May; 10(5):PI74-80. PubMed ID: 15114282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Rathbone J; Dardennes R; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2005 Apr; (2):CD001359. PubMed ID: 15846619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.
    Chou S; Davis C; Li M
    Behav Brain Res; 2021 Apr; 403():113145. PubMed ID: 33515643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.
    Zhang C; Li M
    Behav Pharmacol; 2012 Feb; 23(1):66-79. PubMed ID: 22157143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
    Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
    Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
    Pillai A; Parikh V; Terry AV; Mahadik SP
    J Psychiatr Res; 2007 Aug; 41(5):372-86. PubMed ID: 16564057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.
    Weston-Green K; Huang XF; Deng C
    Behav Brain Res; 2011 Mar; 217(2):337-46. PubMed ID: 21056063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning.
    Song WS; Cha JH; Yoon SH; Cho YS; Park KY; Kim MH
    Neuropharmacology; 2017 Mar; 114():1-11. PubMed ID: 27866902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.